F. Petti

A systems view of epithelial–mesenchymal transition signaling states

Stuart Thomson, James Bean, Sean L. Seymour, 2010, Clinical & Experimental Metastasis.

Peptide, domain, and DNA affinity selection in the identification and quantitation of proteins from complex biological samples.

F. Petti, J. Haley, S. Thomson, 2006, Analytical biochemistry.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors

Siobhan McCormack, E. Brown, F. Petti, 2006, Molecular Cancer Therapeutics.

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

S. Thomson, F. Petti, Izabela Sujka-Kwok, 2008, Clinical & Experimental Metastasis.

Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930

Laura A. Sullivan, Siobhan McCormack, F. Petti, 2005, Molecular Cancer Therapeutics.

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

E. Brown, S. Thomson, F. Petti, 2005, Cancer research.

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

Stuart Thomson, John D. Haley, S. Thomson, 2008, Clinical & Experimental Metastasis.

Phosphotyrosine Signaling Networks in Epidermal Growth Factor Receptor Overexpressing Squamous Carcinoma Cells*S

D. Fenyo, F. Petti, J. Haley, 2005, Molecular & Cellular Proteomics.